Burjeeel Holdings, a leading medical care provider of Super Specialty in the Mena region, has announced a strategic association with Paige, a leading leader in the United States in next -generation technology. The collaboration aims to improve access to advanced cancer diagnoses by implementing the solutions of Paige in the Burjel health network. It also seeks to address global pathologists and accelerate access to rapid and reliable cancer diagnoses, spectularly in unattended communities and emerging markets. The collaboration announced the Global Health Week of the Dhabi duration in the presence of Dr. Shamsheer Vayalil, founder and president or Burjel Holdings.
Paige has developed a set of AI applications that support diagnostic decision making in cancer pathology. Paige*prostate detection, a key component of the suite, is the first AI algorithm approved by the FDA, which works by detecting prostate cancer in core water biopsies. With this association, Burjel Holdings will become one of the first in the region to offer thesis diagnostic tools propelled by AI, reinforcing its commitment to provide timely and accessible cancer care. Paige solutions are designed to increase pathologists, rationalize workflows and increase diagnosis confidence, finally results in better results for patients. The association represents a significant step towards the democratization of advanced care, ensuring that even the most advanced technologies reach patients who need them the most.
“Our collaboration with Paige representatives is a transformative step in the delivery of cancer diagnoses in our network. By incorporating next -generation AI in our pathology services, our goal is “,”, “,”, “,”, “,”, “,”, “,”, “, the markets,”, “holdings.
Paige has obtained multiple regulatory achievements in AI for the pathology, including the designation of innovative devices of the FDA for Paige Pancance Detect, Paige Breast Lymph -node and Paige Prostate Detect. Burjeel Holdings will implement thesis AI applications together with Paige Omniscreen, which simultaneously shows more than 1,600 molecular biomarkers to support the integral diagnosis of cancer and a more personalized treatment.
“The commitment of Burjeeel Holdings with innovation and equitable care throughout the Mena region makes them a powerful ally to help us close the diagnostic gaps and bring the benefits of our technology to more patients, faster. This association helps the generation of the generation of helping world aid in the world and alignments with our vision to standardize access to the diagnosis of the cutting of the cutting Peter Hamilton said, the general manager of the diagnoses, the general manager of the Diagnostic Manager, the General Manager of the Vision.
The association marks a key milestone in the positioning of Burjel Holdings as a regional center for the pathology enabled for AI, with the potential to climb this transformative technology in Mena and beyond.
Follow Emirates 24 | 7 on Google News.
